Admission to trading on AIM

RNS Number:1533U
EiRx Therapeutics PLC
13 January 2004

EiRx Therapeutics plc ("the Company")



Admission to trading on AIM



The Company is pleased to announce that trading in its shares on AIM has
commenced this morning.



EiRx Therapeutics plc's principal activity, undertaken through its subsidiary
EiRx Therapeutics Limited, is the discovery and validation of genes that are
involved in apoptosis, the process through which most cell death takes place. By
identifying these genes, which are potential targets for novel therapeutics,
EiRx creates intellectual property that it out licenses or seeks to exploit by
other means. EiRx Therapeutics Limited is based in Cork, Republic of Ireland.



Following its placing of 15,680,000 shares at 5 pence per share to raise
#784,000, the following shareholders hold more than 3 per cent. of the Company's
issued share capital:


EiRx Pharma Limited                                   81.73%
Peter Hoskins                                          4.47%
Hoodless Brennan & Partners plc                        4.09%
Billam plc                                             3.72%



Billam plc has a beneficial interest in a total of 35.6% of the Company both
through shares it holds directly and indirectly through holdings in EiRX Pharma
Limited.



Copies of the AIM admission document will be available at the offices of Grant
Thornton, Grant Thornton House, Melton Street, Euston Square, London NW1 2EP
until 13 February 2004.



For further information:



Ian Hayes 00 353 21 432 0847

www.eirx.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCFGGMMLFVGDZG